ライフサイエンスコーパス: cladribine

1 relapse can be successfully re-treated with cladribine.

2 rferon alfa-2a and alfa-2b, pentostatin, and cladribine.

3 ens the duration of severe neutropenia after cladribine.

4 monocytes, we conducted a phase II trial of cladribine.

5 o relapse can be successfully retreated with cladribine.

6 to chlorambucil, cisplatin, carboplatin, and cladribine.

7 and on MRI findings in patients treated with cladribine.

8 iagnosis of hairy cell leukemia treated with cladribine.

9 nd poor response to standard treatments like cladribine.

10 stituent at the 2-position present in dG and cladribine.

11 erienced relapse after their first course of cladribine.

12 ended follow-up of HCL patients treated with cladribine.

13 In the first year patients were given cladribine 0.10 mg/kg per day for 7 days as four monthly

14 Of 16 patients who were resistant to cladribine, 11 had a complete remission and 2 had a part

15 Eight patients received cladribine 12 mg/m(2) continuous infusion for 5 days wit

16 om diagnosis, 18 years; and median time from cladribine, 16 years).

17 To assess the efficacy of cladribine (2-chloro-2'-deoxyadenosine) in the treatment

18 high yields of the clinical anticancer drug cladribine (2-chloro-2'-deoxyadenosine).

19 rt efficient syntheses of the clinical agent cladribine (2-chloro-2'-deoxyadenosine, CldAdo), which i

20 Since cladribine (2-chlorodeoxyadenosine [2-CdA]) and mitoxant

21 Cladribine (2-chlorodeoxyadenosine [2-CdA]) is a synthet

22 Cladribine (2-chlorodeoxyadenosine [2-CdA]; Ortho Biotec

23 Cladribine (2-chlorodeoxyadenosine) induces complete rem

24 ability (F value) of 2-chlorodeoxyadenosine (cladribine; 2-CdA) after multiple oral administrations,

25 Having relapsed after prior treatment with cladribine, 24 HCL pts (21 male, 3 female) with a median

26 d to evaluate the effectiveness of high-dose cladribine (2CDA) for treatment of chronic myelogenous l

27 The optimal dose and schedule for cladribine (2CdA) therapy of malignant hematologic disea

28 lity to transport the nucleoside analog drug cladribine, 2CdA, (rCNT2 > > > hCNT2) to identify the cr

29 ents received cladribine 5.25 mg/kg (n=204), cladribine 3.5 mg/kg (n=206), or placebo (n=206).

30 r 96 weeks, 178 (44%) of 402 patients in the cladribine 3.5 mg/kg group and 189 (46%) of 411 patients

31 r 48 weeks, 208 (54%) of 384 patients in the cladribine 3.5 mg/kg group and 222 (56%) of 396 patients

32 r 24 weeks, 266 (67%) of 395 patients in the cladribine 3.5 mg/kg group and 283 (70%) of 406 in the c

33 5.25 mg/kg group, 168 (82%) patients in the cladribine 3.5 mg/kg group, and 162 (79%) patients in th

34 other treatments; 5 pts were retreated with cladribine, 3 underwent splenectomy, and 1 received pent

35 essed for eligibility, 616 patients received cladribine 5.25 mg/kg (n=204), cladribine 3.5 mg/kg (n=2

36 g group and 189 (46%) of 411 patients in the cladribine 5.25 mg/kg group were free from disease activ

37 3.5 mg/kg group and 283 (70%) of 406 in the cladribine 5.25 mg/kg group were free from disease activ

38 g group and 222 (56%) of 396 patients in the cladribine 5.25 mg/kg group were free from disease activ

39 s were reported in 165 (81%) patients in the cladribine 5.25 mg/kg group, 168 (82%) patients in the c

40 Cladribine 5.6 mg/m(2) given IV over 2 hours daily for 5

41 ilure of one prior chemotherapy (n = 2) with cladribine (5.6 mg/m(2) given intravenously over 2 hours

42 day courses of Ara-C (1 g/m(2) per day) plus cladribine (9 mg/m(2) per day) followed by maintenance t

43 2-Chloro-2'-deoxyadenosine [CldAdo (cladribine)], a novel effective antileukemic agent, was

44 previous observations that single courses of cladribine administered to patients with HCL induce high

45 The median number of cycles of cladribine administered was 2.5 (range, 1-6).

46 In addition, dG and cladribine adopt the anti conformation, in contrast to t

47 ared with 105 historic controls treated with cladribine alone.

48 ssover study was started in 1992 to evaluate cladribine, an immunosuppressive drug, in the treatment

49 An international phase 2 study combining cladribine and cytarabine (Ara-C) was initiated for pati

50 Cladribine and interferon alpha were therapeutically the

51 Although the nucleoside analogs cladribine and pentostatin produce high response rates i

52 eatment with the nucleoside purine analogues cladribine and pentostatin results in lengthy remissions

53 ed a study of priming filgrastim followed by cladribine and then filgrastim again to determine if fil

54 Thirty-five patients received filgrastim and cladribine and were compared with 105 historic controls

55 antineoplastic, 2-chloro-2'-deoxyadenosine (cladribine) and puromycin, a protein synthesis inhibitor

56 lzomib), nucleoside analogs (fludarabine and cladribine), and ibrutinib.

57 ncer nucleoside drugs, including cytarabine, cladribine, and fludarabine.

58 ssion-free survival (P = .007) after initial cladribine, and shorter overall survival from diagnosis

59 Thus, the combination of cladribine/Ara-C is effective therapy for refractory mul

60 s with hairy cell leukemia were treated with cladribine at 0.087 or 0.1 mg/kg body weight per day by

61 showed that short-course oral treatment with cladribine at cumulative doses of 3.5 and 5.25 mg/kg ove

62 able patients treated with second courses of cladribine at first relapse, 33 (62%) achieved complete

63 f purine nucleoside analogs (pentostatin and cladribine) changed the natural history of this rare dis

64 of phase 3 trials and cross-study analyses, cladribine compared favorably with fludarabine, another

65 A course of cladribine constituted a 7-day continuous intravenous in

66 urvival for all patients following the first cladribine course was 231 months, and 251 months from di

67 From the 358-person Scripps Clinic cladribine database, we identified 19 patients in contin

68 le, has only modest single-agent activity in cladribine-failed HCL patients when compared with other

69 Best responses to BL22 after cladribine failure are achieved before the patients deve

70 y to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy

71 Treatment with cladribine followed by rituximab is effective tk;4and ma

72 pproved novel agents may act in synergy with cladribine for these conditions and should be incorporat

73 /=40 years of age at diagnosis) treated with cladribine from the Scripps Clinic HCL Database, of whom

74 dverse events that were more frequent in the cladribine groups included lymphocytopenia (21.6% in the

75 nine patients with HCL who were treated with cladribine had at least 7 years of follow-up.

76 Cladribine has been noted to have particular activity am

77 Cladribine has high efficacy and a favorable acute and l

78 Thus, cladribine has major activity in adult LCH and warrants

79 Cladribine has moderate clinical efficacy in the treatme

80 o treatment with purine analogues, including cladribine, has a poor prognosis.

81 rete et al report the safety and efficacy of cladribine in 68 adult patients with mastocytosis.

82 ately 10-fold loss of cytostatic activity of cladribine in MCF-7.Hyor cells and observed a rapid and

83 he routine adjunctive use of filgrastim with cladribine in the treatment of HCL cannot be recommended

84 cal advantage from the use of filgrastim and cladribine in the treatment of HCL.

85 toreductive therapies (eg, interferon-alpha, cladribine) in this setting.

86 Single courses of cladribine induce high rates of complete and durable res

87 t B-cell disorder in which single courses of cladribine induce high rates of complete responses.

88 The purine analogs, pentostatin and cladribine, induce high remission rates when used as fir

89 Single courses of cladribine induced long-lasting complete responses in th

90 Cladribine induces protracted remissions in patients wit

91 While cladribine is best known for the treatment of hairy cell

92 Kinetic analysis reveals that cladribine is phosphorylated at the highest efficiency w

93 Because cladribine is potently toxic to monocytes, we conducted

94 e analog 2-chloro-2'-deoxyadenosine (CldAdo; cladribine) is effective in the treatment of hairy cell

95 re stratified into three groups: response to cladribine less than 1 year, those with a response lasti

96 e initial very high response rates following cladribine, many patients (pts) ultimately relapse.

97 bine/melphalan combination and 87.5% for the cladribine/melphalan combination.

98 for relapsed/refractory HCL after first-line cladribine (n = 3) or after multiple lines of therapy (n

99 e 3 study we investigated the effect of oral cladribine on conversion to clinically definite MS in pa

100 we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a

101 ate whether the addition of a purine analog, cladribine or fludarabine, to the standard induction reg

102 (daunorubicin plus cytarabine), DAC (DA plus cladribine), or DAF (DA plus fludarabine).

103 T1), accumulation of [(3)H]cytarabine, [(3)H]cladribine, or [(3)H]fludarabine was reduced by each of

104 nhanced cytotoxicity induced by fludarabine, cladribine, or chlorambucil.

105 rtial response (PR) after a single course of cladribine (overall response rate, 100%).

106 Many treatments exist, including cladribine, pentostatin, interferon-alpha, splenectomy,

107 nfusions of 0.10 mg, 0.05 mg, and 0.05 mg of cladribine per kg of body weight per day for 7 consecuti

108 Cladribine provides immunomodulation through selective t

109 e analogues of medicinal importance, such as cladribine, require phosphorylation by deoxycytidine kin

110 However, cladribine's impressive activity in other lymphoprolifer

111 single-arm phase 2 trials have demonstrated cladribine's potency across the full spectrum of lymphoi

112 Both doses of cladribine significantly delayed MS diagnosis compared w

113 ents, the condition of patients who received cladribine stabilized or even improved slightly.

114 Among patients who received cladribine tablets (either 3.5 mg or 5.25 mg per kilogra

115 io to receive one of two cumulative doses of cladribine tablets (either 3.5 mg or 5.25 mg per kilogra

116 ng were randomly assigned (1:1:1) to receive cladribine tablets at cumulative doses of 5.25 mg/kg or

117 The effects of cladribine tablets on freedom from disease activity were

118 Treatment with cladribine tablets significantly increased the proportio

119 Treatment with cladribine tablets significantly reduced relapse rates,

120 s clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (C

121 We assessed the effect of two doses of cladribine tablets versus placebo on the proportion of p

122 .26 x 10(9)/L (2.5-fold increase), and after cladribine, the median nadir ANC in the filgrastim-treat

123 Cladribine therapy in first-line treatment or later.

124 Response to initial single-agent cladribine therapy is suboptimal; these patients should

125 Their median age at the time of cladribine therapy was 62 years (age range, 40-78 years)

126 Among patients who responded to cladribine therapy, the median duration of clinical resp

127 We attribute this to the ability of cladribine to combine advantageous properties from dA (f

128 iency of PNPHyor-catalyzed phosphorolysis of cladribine to its less toxic base 2-chloroadenine (Km =

129 The addition of cladribine to the standard induction regimen is associat

130 could clarify the potential effects of oral cladribine treatment in the early stages of MS.

131 Cladribine treatment of hairy cell leukemia (HCL) is com

132 dicate that HCL is potentially curable after cladribine treatment.

133 nd -1 and then again after the completion of cladribine until the absolute neutrophil count (ANC) was

134 Cladribine was administered at 0.1 mg/kg/d by continuous

135 Cladribine was administered to 13 LCH patients at 0.14 m

136 small study of patients with de novo B-PLL, cladribine was an active agent that induced a high overa

137 At trial termination on Oct 25, 2011, cladribine was associated with a risk reduction versus p

138 ationally designed antineoplastic therapies, cladribine was identified as a lymphocyte-specific agent

139 The safety profile of cladribine was similar to that noted in a trial in patie

140 Cladribine was the most commonly used chemotherapeutic a

141 Cladribine was used as the first-line treatment in 9 pat

142 atients who had been treated previously with cladribine were crossed over to placebo.

143 nders subsequent to a single 7-day course of cladribine were without minimal residual disease (MRD) a